Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Symrise AG    SY1   DE000SYM9999

SYMRISE AG

(SY1)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 10/26 04:37:17 pm
112.1 EUR   -1.71%
10/21Q3 2020 : Strong growth with good profitability
AQ
10/20PROBI : acquires shares in Vital Nutrients Holdings and enters into strategic partnership
AQ
10/19SYMRISE AG : UBS reaffirms its Neutral rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Symrise: Hydrolite® 5P- multifunctional excipient suitable for pharmaceutical applications

share with twitter share with LinkedIn share with facebook
08/12/2020 | 05:37am EDT

25 years after the launch of its multifunctional ingredient Hydrolite® 5, Symrise is now launching its pharmaceutical grade Pentylene Glycol, Hydrolite® 5P. A Drug Master File (DMF) is available for this product, which will introduce the benefits of Hydrolite®5 green to the pharmaceutical and dermo-cosmetic industries. The ingredient uses a by-product of the sugar cane industry and brings sustainable benefits from a renewable source.

"Hydrolite® 5P hydrates the skin and bolsters the efficacy of active ingredients used in the formulations" says Najeeb Hakimi, Product Manager at Symrise. "With Hydrolite® 5P, our customers can improve the efficacy of formulations with the same dose of active ingredients." Hydrolite® 5P enhances formulation esthetics and improves the skin feel of formulations. And because it can aid the product protection system, it helps reduce the amount of preservatives used in a product.

Hydrolite® 5P is entirely made from the by-product from the sugar cane industry. It perfectly fits into the sustainability strategy of Symrise. Within this strategy, the company emphasizes the importance of comprehensive transparency that benefits customers and end consumers.

.

(C) 2020 M2 COMMUNICATIONS, source M2 PressWIRE


share with twitter share with LinkedIn share with facebook
All news about SYMRISE AG
10/21Q3 2020 : Strong growth with good profitability
AQ
10/20PROBI : acquires shares in Vital Nutrients Holdings and enters into strategic pa..
AQ
10/19SYMRISE AG : UBS reaffirms its Neutral rating
MD
10/19PROBI : Presentation of Probi's Q3 report
AQ
10/12SYMRISE AG : DZ Bank downgrades from Neutral to Sell rating
MD
10/08SYMRISE AG : Gets a Neutral rating from Bernstein
MD
10/07SYMRISE AG : UBS sticks Neutral
MD
10/05SYMRISE AG : Goldman Sachs remains its Buy rating
MD
10/01SYMRISE AG : JP Morgan remains a Sell rating
MD
10/01SYMRISE AG : Deutsche Bank reaffirms its Buy rating
MD
More news
Financials
Sales 2020 3 608 M 4 265 M 4 265 M
Net income 2020 345 M 408 M 408 M
Net Debt 2020 1 425 M 1 685 M 1 685 M
P/E ratio 2020 46,0x
Yield 2020 0,92%
Capitalization 15 269 M 18 045 M 18 051 M
EV / Sales 2020 4,63x
EV / Sales 2021 4,33x
Nbr of Employees 10 413
Free-Float 91,2%
Chart SYMRISE AG
Duration : Period :
Symrise AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SYMRISE AG
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 106,32 €
Last Close Price 112,75 €
Spread / Highest target 20,6%
Spread / Average Target -5,70%
Spread / Lowest Target -28,2%
EPS Revisions
Managers
NameTitle
Heinz-Jürgen Bertram Chief Executive Officer
Michael König Chairman-Supervisory Board
Olaf Klinger Chief Financial Officer
Horst-Otto Gerberding Member-Supervisory Board
Peter Winkelmann Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
SYMRISE AG20.20%18 283
ECOLAB INC.6.16%58 467
GIVAUDAN SA27.81%39 466
SIKA AG27.14%36 173
EMS-CHEMIE HOLDING AG31.50%21 610
CRODA INTERNATIONAL PLC22.34%10 449